-

02:09:23 PM

APLIF Stock News

APLIF - Appili Therapeutics Inc

09/27/23 7:21 PM

OTC : APLIF

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update

Most recently, the Company’ s ATI-1501 program for the treatment of anaerobic bacterial infections, received U.S. Food and Drug Administration approval on September 22, 2023. Appili’ s developmental program ATI-1701 for the prevention of F. Tularensis, has received an award of approximately US $7.3 million from the U.S. Air Force Academy. The initial funding...

RHEA-AI

neutral

09/27/23 7:27 AM

OTC : APLIF

Appili Therapeutics Presents at the 10th International Tularemia Conference

Gelhaus.“ We remain encouraged by recently announced U.S. government funding commitments for ATI-1701 and look forward to collaborating with other tularemia experts toward the first approved vaccine for the prevention of weaponized tularemia.”. Since it is a highly infectious pathogen capable of causing severe illness, medical counter measures for F....

RHEA-AI

neutral

09/25/23 7:54 AM

OTC : APLIF

fda approval

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC received approval from the U.S. Food and Drug Administration for Metronidazole Oral Suspension 500 mg/5mL.

RHEA-AI

neutral

08/11/23 4:50 PM

OTC : APLIF

earnings

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

"During this quarter, we executed an agreement with United States Air Force Academy for an initial amount of US $7.3 million in funding from the Defense Threat Reduction Agency and USAFA for our ATI-1701 vaccine, a crucial defense against Tularemia, which is a top-priority biothreat. This agreement provides the first stage of funding from the previously...

RHEA-AI

neutral

06/29/23 7:26 AM

OTC : APLIF

Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that it has entered into a definitive agreement with respect to an unsecured C $300,000 bridge loan from Bloom Burton& Co. Inc.. As previously announced, Appili entered into a cooperative agreement with the...

RHEA-AI

neutral

06/23/23 5:07 PM

OTC : APLIF

Appili Therapeutics – Press Release Correction

Appili Therapeutics Inc., announced today a correction to its press release entitled“ Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results” which was issued on June 23, 2023. The Initial Press Release, under the heading entitled“ ATI-1501, with Patent Coverage through 2039” incorrectly stated that it is expected that the FDA review...

RHEA-AI

neutral

06/23/23 7:21 AM

OTC : APLIF

earnings

Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results

“During this fiscal year, the Defense Threat Reduction Agency in partnership with the U.S. Air Force Academy approved approximately US $14 million in funding over two years for the advancement of ATI-1701, our vaccine against Tularemia, a top-priority biothreat. ATI-1701, Biodefense Vaccine Candidate with Secured Funding from U.S. Air Force Academy.

RHEA-AI

neutral

05/24/23 7:19 AM

OTC : APLIF

Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Patent and Trademark Office has published patent claims for ATI-1501 under the U.S. Application No. 18/ 072,154 filed on November 30, 2022 and titled“ Oral Formulations of Metronidazole and...

RHEA-AI

neutral

05/08/23 7:38 AM

OTC : APLIF

Appili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the Company has executed the initial contract with the U.S. Air Force Academy for the previously announced funding of the ATI-1701 program. This contract represents the first stage of funding from the previously...

RHEA-AI

neutral

04/18/23 7:17 AM

OTC : APLIF

conferences

Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Dr. Don Cilla, Appili President and Chief Executive Officer, will present at the Bloom Burton& Co. Healthcare Investor Conference taking place on April 25 and 26, 2023.. About Bloom Burton& Co. Bloom Burton& Co. is a...

RHEA-AI

neutral